RecruitingSolid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Eligible age
18+ yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Sponsor: Mirati Therapeutics Inc.
You may qualify if…
- ✓ Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
- ✓ Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.
You may not qualify if…
- ✕ Participant is not eligible for study treatment per the parent study eligibility criteria.
- ✕ Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
- ✕ Participants not receiving clinical benefit from parent study drug as assessed by the investigator.
- ✕ Other protocol defined inclusion/exclusion criteria applies.
Where it's recruiting
Arizona
Phoenix
California
Bellflower · Long Beach
Delaware
Newark
Florida
St. Petersburg
Kansas
Wichita
Massachusetts
Boston
Minnesota
Rochester · Saint Paul
Nebraska
Omaha
Oregon
Eugene
Tennessee
Germantown
Texas
Bedford · Dallas · Grapevine
Washington
Bellingham
Source: ClinicalTrials.gov · NCT07415031 · last updated 2026-11-12